サンプル依頼リスト カート
  • English
  • Korean
表紙：ヒストプラズマ症治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415741

ヒストプラズマ症治療の世界市場レポート 2024年

Histoplasmosis Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ヒストプラズマ症治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ヒストプラズマ症治療市場規模は近年力強く成長しています。2023年の47億4,000万米ドルから2024年には51億3,000万米ドルに、CAGR8.2％で拡大します。実績期間の成長は、地理的な流行、認知度と診断、世界の健康への取り組み、研究開発、医薬品開発に起因しています。

ヒストプラズマ症治療市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.2％で70億4,000万米ドルに成長します。予測期間の成長は、遠隔医療と遠隔診察、患者教育とサポート、償還政策に起因しています。予測期間の主な動向には、抗真菌剤耐性管理、併用療法、免疫調節療法、高度診断ツールが含まれます。

慢性疾患の急増は、当面のヒストプラズマ症治療市場拡大の大きな促進要因になると予測されます。慢性疾患は、3ヶ月以上持続し、時間の経過とともに悪化する可能性があることを特徴とし、ますます蔓延しています。ヒストプラズマ症は、呼吸器の健康を増進し、炎症を緩和し、免疫系機能を強化し、最終的には慢性疾患と闘う人々の生活の質を高めるという重要な役割を担っています。例えば、米国の国立医学図書館が2023年1月に発表したところによると、少なくとも1つの慢性疾患に罹患している米国の50歳以上の人口は99.5％急増し、2020年の7,152万2,000人から2050年には1億4,266万人に急増すると予測されています。その結果、慢性疾患の罹患率の上昇は、ヒストプラズマ症治療市場の成長を推進する極めて重要な要因となっています。

ヒト免疫不全ウイルス（HIV）の蔓延が、ヒストプラズマ症治療市場拡大の大きな原動力になると予測されています。HIVは、CD4細胞（T細胞）を標的とし、感染症や病気と闘う免疫系の能力を弱めるウイルスであり、その流行はますます拡大しています。例えば、2023年7月現在、スイスに本部を置く国連機関である世界保健機関（WHO）によると、2022年に世界で報告されたHIV感染者数は3,900万人で、HIVに関連した死亡者数は63万人です。その結果、HIVの蔓延がヒストプラズマ症治療市場の成長を促進する要因となっています。

2023年のヒストプラズマ症治療市場では北米が最大地域でした。ヒストプラズマ症レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のヒストプラズマ症治療市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アムホテリシンB
  • イトラコナゾール
  • ケトコナゾール
  • その他
  • 世界のヒストプラズマ症治療市場、投与方法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 注射可能
  • 経口
  • その他
  • 世界のヒストプラズマ症治療市場、患者タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 小児
  • 成人
  • 世界のヒストプラズマ症治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • プライベートクリニック
  • ドラッグストア
  • 小売薬局
  • eコマース
  • その他

第7章 地域および国の分析

  • 世界のヒストプラズマ症治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のヒストプラズマ症治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ヒストプラズマ症治療市場の競合情勢
  • ヒストプラズマ症治療市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Ltd.
    • F. Hoffmann-La Roche AG
    • Merck and Co. Inc.
    • AbbVie Inc.

第31章 その他の主要および革新的な企業

  • Novartis AG
  • Sanofi S.A
  • Bristol Myers Squibb
  • AstraZeneca Plc
  • Abbott laboratories
  • GSK Plc
  • Eli Lilly and Company
  • Gilead Sciences
  • Teva Pharmaceutical Industries Ltd.
  • Astellas pharma US Inc.
  • Mylan N.V.
  • Biogen Inc.
  • Bausch Health Companies Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • AB Science

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12340

“Histoplasmosis Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on histoplasmosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for histoplasmosis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The histoplasmosis treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Type: Amphotericin B; Itraconazole; Ketoconazole; Other Drug Type
  • 2) By Mode of Administration: Injectable; Oral; Other Mode Of Administration
  • 3) By Patient Type: Pediatric; Adult
  • 4) By End-User: Hospital Pharmacies; Private Clinics; Drug Stores; Retail Pharmacies; E-Commerce; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Histoplasmosis treatment encompasses a range of medical interventions and therapies aimed at combatting the fungal infection caused by the Histoplasma capsulatum fungus. This particular fungus is commonly found in soil, especially in areas where substantial accumulations of bird or bat droppings exist. The approach to treatment is tailored to factors such as the infection's severity, the overall health of the patient, and the presence of any underlying medical conditions.

Histoplasmosis treatment encompasses a range of medical interventions and therapies aimed at combatting the fungal infection caused by the Histoplasma capsulatum fungus. This particular fungus is commonly found in soil, especially in areas where substantial accumulations of bird or bat droppings exist. The approach to treatment is tailored to factors such as the infection's severity, the overall health of the patient, and the presence of any underlying medical conditions.

The histoplasmosis treatment market research report is one of a series of new reports from The Business Research Company that provides histoplasmosis treatment market statistics, including histoplasmosis treatment industry global market size, regional shares, competitors with a histoplasmosis treatment market share, detailed histoplasmosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the histoplasmosis treatment industry. This histoplasmosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The histoplasmosis treatment market size has grown strongly in recent years. It will grow from $4.74 billion in 2023 to $5.13 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to geographic prevalence, awareness and diagnosis, global health initiatives, research and drug development.

The histoplasmosis treatment market size is expected to see strong growth in the next few years. It will grow to $7.04 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to telemedicine and remote consultations, patient education and support, reimbursement policies. Major trends in the forecast period include antifungal resistance management, combination therapies, immunomodulatory therapies, advanced diagnostic tools.

The surge in chronic diseases is anticipated to be a significant driver for the expansion of the histoplasmosis treatment market in the foreseeable future. Chronic illnesses, characterized by lasting three months or more and potentially worsening over time, are becoming increasingly prevalent. Histoplasmosis treatment plays a crucial role in enhancing respiratory health, mitigating inflammation, bolstering immune system function, and ultimately elevating the quality of life for individuals grappling with chronic diseases. For instance, in January 2023, as per the National Library of Medicine, a US-based agency, the population of individuals aged 50 and above in the US afflicted with at least one chronic condition is projected to surge by 99.5%, skyrocketing from 71.522 million in 2020 to a staggering 142.66 million by 2050. Consequently, the escalating incidence of chronic diseases stands as a pivotal factor propelling the growth of the histoplasmosis treatment market.

The escalating prevalence of human immunodeficiency virus (HIV) is projected to be a major driving force behind the expansion of the histoplasmosis treatment market in the foreseeable future. HIV, a virus that targets CD4 cells (T cells) and weakens the immune system's ability to combat infections and diseases, has become increasingly prevalent. Histoplasmosis treatment plays a vital role in managing the fungal infection for AIDS patients, aiding in the prevention of disseminated disease and reducing mortality through the use of antifungal medications like itraconazole or amphotericin B. For instance, as of July 2023, according to the World Health Organization, a Switzerland-based United Nations agency, there were 39 million reported cases of HIV globally in 2022, resulting in 630,000 deaths from HIV-related causes. Consequently, the mounting prevalence of HIV is a key driver in the growth of the histoplasmosis treatment market.

The shortage of awareness surrounding histoplasmosis is expected to hinder the expansion of the treatment market for this condition in the foreseeable future. Histoplasmosis, stemming from the Histoplasma fungus present in soil, poses a risk to individuals, especially those in proximity to contaminated materials. This fungal infection is commonly contracted through the inhalation of spores present in bird and bat droppings. For instance, as of June 2023, as reported by the U.S. Department of Health and Human Services, the diagnosis of histoplasmosis may experience delays due to a lack of sufficient awareness regarding the condition. Histoplasmosis is not categorized as a notifiable disease and is excluded from most public health surveillance systems, making it difficult to accurately gauge its true prevalence. Consequently, the limited awareness surrounding the disease stands as a significant obstacle impeding the growth of the histoplasmosis treatment market.

Key players in the histoplasmosis treatment market are pioneering inventive approaches to fortify their market presence. Breakthroughs in antifungal drug research have paved the way for novel compounds and strategies specifically designed to combat invasive histoplasmosis. For instance, in June 2022, Apex Laboratories, an India-based pharmaceutical company, unveiled an advanced iteration of Itraconazole Capsules Supra Bioavailable in 65 and 130 mg variants-a potent therapeutic option for effectively managing fungal infections. These capsules deliver a remarkable 90% of active medicine to the biological system at a reduced dosage, catering to a range of fungal infections like blastomycosis, histoplasmosis, and aspergillosis. Their creation involves cutting-edge spray granulation technology, which accelerates the dissolution rate of itraconazole. This medication is uniformly present in solid dispersion, sans pellets. Such innovative techniques enhance the bioavailability of medications with low solubility.

In April 2021, the US-based biotechnology and pharmaceutical giant, Pfizer Inc., completed the acquisition of Amplyx Pharmaceuticals Inc. for an undisclosed sum. This strategic move is geared towards augmenting Pfizer's anti-infective portfolio and deepening its expertise in the realm of infectious diseases. Amplyx Pharmaceuticals Inc., also based in the United States, is renowned for its development of life-saving treatments and therapies, including crucial drugs for histoplasmosis treatment, like amphotericin B.

Major players in the histoplasmosis treatment market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol Myers Squibb, AstraZeneca PLC, Abbott laboratories, GSK PLC, Eli Lilly and Company, Gilead Sciences, Teva Pharmaceutical Industries Ltd., Astellas pharma US Inc., Mylan N.V., Biogen Inc., Bausch Health Companies Inc., Mitsubishi Tanabe Pharma Corporation, AB Science, Ionis Pharmaceuticals Inc., Advanz Pharma Corp., Leadiant Biosciences, IMMY, Sigma Tau Pharmaceuticals Inc.

North America was the largest region in the histoplasmosis treatment market in 2023. The regions covered in histoplasmosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the histoplasmosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The histoplasmosis treatment consists of sales of antifungal medications and posaconazole. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Histoplasmosis Treatment Market Characteristics

3. Histoplasmosis Treatment Market Trends And Strategies

4. Histoplasmosis Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Histoplasmosis Treatment Market Size and Growth

  • 5.1. Global Histoplasmosis Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Histoplasmosis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Histoplasmosis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Histoplasmosis Treatment Market Segmentation

  • 6.1. Global Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Amphotericin B
  • Itraconazole
  • Ketoconazole
  • Other Drug Type
  • 6.2. Global Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injectable
  • Oral
  • Other Mode Of Administration
  • 6.3. Global Histoplasmosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatric
  • Adult
  • 6.4. Global Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce
  • Other End-Users

7. Histoplasmosis Treatment Market Regional And Country Analysis

  • 7.1. Global Histoplasmosis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Histoplasmosis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Histoplasmosis Treatment Market

  • 8.1. Asia-Pacific Histoplasmosis Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Histoplasmosis Treatment Market

  • 9.1. China Histoplasmosis Treatment Market Overview
  • 9.2. China Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Histoplasmosis Treatment Market

  • 10.1. India Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Histoplasmosis Treatment Market

  • 11.1. Japan Histoplasmosis Treatment Market Overview
  • 11.2. Japan Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Histoplasmosis Treatment Market

  • 12.1. Australia Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Histoplasmosis Treatment Market

  • 13.1. Indonesia Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Histoplasmosis Treatment Market

  • 14.1. South Korea Histoplasmosis Treatment Market Overview
  • 14.2. South Korea Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Histoplasmosis Treatment Market

  • 15.1. Western Europe Histoplasmosis Treatment Market Overview
  • 15.2. Western Europe Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Histoplasmosis Treatment Market

  • 16.1. UK Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Histoplasmosis Treatment Market

  • 17.1. Germany Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Histoplasmosis Treatment Market

  • 18.1. France Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Histoplasmosis Treatment Market

  • 19.1. Italy Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Histoplasmosis Treatment Market

  • 20.1. Spain Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Histoplasmosis Treatment Market

  • 21.1. Eastern Europe Histoplasmosis Treatment Market Overview
  • 21.2. Eastern Europe Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Histoplasmosis Treatment Market

  • 22.1. Russia Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Histoplasmosis Treatment Market

  • 23.1. North America Histoplasmosis Treatment Market Overview
  • 23.2. North America Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Histoplasmosis Treatment Market

  • 24.1. USA Histoplasmosis Treatment Market Overview
  • 24.2. USA Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Histoplasmosis Treatment Market

  • 25.1. Canada Histoplasmosis Treatment Market Overview
  • 25.2. Canada Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Histoplasmosis Treatment Market

  • 26.1. South America Histoplasmosis Treatment Market Overview
  • 26.2. South America Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Histoplasmosis Treatment Market

  • 27.1. Brazil Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Histoplasmosis Treatment Market

  • 28.1. Middle East Histoplasmosis Treatment Market Overview
  • 28.2. Middle East Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Histoplasmosis Treatment Market

  • 29.1. Africa Histoplasmosis Treatment Market Overview
  • 29.2. Africa Histoplasmosis Treatment Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Histoplasmosis Treatment Market, Segmentation By Mode of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Histoplasmosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Histoplasmosis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Histoplasmosis Treatment Market Competitive Landscape
  • 30.2. Histoplasmosis Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck and Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Histoplasmosis Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi S.A
  • 31.3. Bristol Myers Squibb
  • 31.4. AstraZeneca Plc
  • 31.5. Abbott laboratories
  • 31.6. GSK Plc
  • 31.7. Eli Lilly and Company
  • 31.8. Gilead Sciences
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Astellas pharma US Inc.
  • 31.11. Mylan N.V.
  • 31.12. Biogen Inc.
  • 31.13. Bausch Health Companies Inc.
  • 31.14. Mitsubishi Tanabe Pharma Corporation
  • 31.15. AB Science

32. Global Histoplasmosis Treatment Market Competitive Benchmarking

33. Global Histoplasmosis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Histoplasmosis Treatment Market

35. Histoplasmosis Treatment Market Future Outlook and Potential Analysis

  • 35.1 Histoplasmosis Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Histoplasmosis Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Histoplasmosis Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer